Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles.

ABSTRACT: New drugs targeting bile acid metabolism are currently being evaluated in clinical studies for their potential to treat cholestatic liver diseases, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Changes in bile acid metabolism, however, translate into an alteration of plasma cholesterol and triglyceride concentrations, which may also affect cardiovascular outcomes in such patients. This review attempts to gain insight into this matter and improve our understanding of the interactions between bile acid and lipid metabolism. Bile acid sequestrants (BAS), which bind bile acids in the intestine and promote their faecal excretion, have long been used in the clinic to reduce LDL cholesterol and, thereby, atherosclerotic cardiovascular disease (ASCVD) risk. Ho

SUBMITTER: Zhang B 

PROVIDER: S-EPMC8745251 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature